Up Close with Epcoritamab
Last Updated: January 15, 2026
Discover more about epcoritamab-bysp (EPKINLY®).
Related Resources:
PQI in Action
PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/09/2025
PQI
PQI: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 05/02/2025
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: April 1, 2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Bispecific Antibody Therapy Resource Guide
Last Updated: 10/28/2025
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Up Close with Linvoseltamab
Last Updated: 05/16/2025